Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annexon, Inc.

2.52
-0.1200-4.55%
Pre-market: 2.49-0.0300-1.19%08:33 EDT
Volume:724.52K
Turnover:1.86M
Market Cap:276.48M
PE:-2.16
High:2.67
Open:2.66
Low:2.51
Close:2.64
Loading ...

BRIEF-Annexon Appoints William "BJ" Jones to Board of Directors

Reuters
·
10 Jan

Annexon appoints William Jones to board of directors

TIPRANKS
·
10 Jan

Annexon Expands Board of Directors With Appointment of Commercial Executive William “Bj” Jones

THOMSON REUTERS
·
10 Jan

Press Release: Annexon Expands Board of Directors with Appointment of Commercial Executive William "BJ" Jones

Dow Jones
·
10 Jan

Annexon (ANNX) Surges with Promising Phase 3 Results for Guillain-Barré Syndrome Treatment

TIPRANKS
·
23 Dec 2024

Annexon Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Dec 2024

Buy Rating for Annexon Biosciences: ANX005 Shows Promising Results in GBS Treatment

TIPRANKS
·
17 Dec 2024

Annexon Biosciences Positioned for Success with Promising ANX005 Study in GBS

TIPRANKS
·
17 Dec 2024

Promising Outlook for Annexon Biosciences: ANX005’s Superior Efficacy and Potential Catalysts Drive Buy Rating

TIPRANKS
·
17 Dec 2024

BRIEF-Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
17 Dec 2024

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Dec 2024

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
17 Dec 2024

Annexon Biosciences’ ANX005: Strong Buy Rating Backed by Promising Efficacy and Sales Potential

TIPRANKS
·
17 Dec 2024

Annexon announces topline results from RWE study of ANX005 in GBS

TIPRANKS
·
16 Dec 2024

Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-BarrÉ Syndrome (Gbs)

THOMSON REUTERS
·
16 Dec 2024

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

GlobeNewswire
·
16 Dec 2024